1. Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events...

1. Gepotidacin was non-inferior to ceftriaxone plus azithromycin for the primary outcome of microbiological success. 2. There were no serious...

1. Ischemic stroke occurred less often in patients with atrial fibrillation on DOACs compared to those on placebo. 2. Patients...

1. Perinatal mortality and neonatal morbidity were comparable between the atosiban and placebo groups. 2. Maternal adverse events were similar...

1. Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the pembrolizumab group. 2. Grade...

1. There was no significant difference in functional outcome between both groups at 96 weeks. 2. Exenatide was safe and...

1. There were no gastric and adrenal puncture instances among patients who underwent radio-ablation in both groups. 2. Majority of...

1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events...

1. 5-year breast cancer-specific survival was comparable between annual and less frequent mammography groups. 2. Less-frequent mammographic surveillance showed a...

1. Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events...